Veru Inc is trading 12.6% down at $2.97 in pre-market, extending a pullback that followed a massive rally triggered by a clinical trial supply agreement with Novo Nordisk.
- The stock jumped 88.0% on June 4 after the deal was announced but fell 19.6% on June 5 amid profit-taking.
- Current pre-market weakness suggests a continued unwinding of short-term speculative buying in a relatively quiet macro and news environment.